• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在临床侵袭性神经母细胞瘤中显著的微血管增殖。

Prominent microvascular proliferation in clinically aggressive neuroblastoma.

作者信息

Peddinti Radhika, Zeine Rana, Luca Dragos, Seshadri Roopa, Chlenski Alexandre, Cole Kristina, Pawel Bruce, Salwen Helen R, Maris John M, Cohn Susan L

机构信息

Department of Pediatrics, Children's Memorial Hospital, Chicago, Illinois, USA.

出版信息

Clin Cancer Res. 2007 Jun 15;13(12):3499-506. doi: 10.1158/1078-0432.CCR-07-0237.

DOI:10.1158/1078-0432.CCR-07-0237
PMID:17575212
Abstract

PURPOSE

Tumor vasculature is disorganized and glomeruloid microvascular proliferation (MVP) has been identified as a poor prognosticator in some adult cancers. To determine the clinical significance of MVP, including glomeruloid MVP in neuroblastoma, we initially examined vessel architecture in tumor sections from 51 children diagnosed at Children's Memorial Hospital (CMH) and subsequently evaluated 154 neuroblastoma tumors on a tissue microarray constructed at Children's Hospital of Philadelphia (CHOP).

EXPERIMENTAL DESIGN

H&E sections were examined for the presence of structurally abnormal vessels and further characterized by immunostaining for CD31 and von Willebrand factor to highlight endothelial cells and alpha-smooth muscle actin for pericytes. Tumors with thickened walls containing a complete layer of hypertrophic endothelial cells plus additional layers of vascular mural cells were classified as MVP positive. Associations between MVP and established clinicopathologic features and outcome were assessed.

RESULTS

In both series, MVP was significantly associated with Schwannian stroma-poor histology (CMH, P = 0.008; CHOP, P < 0.001) and decreased survival probability (CMH, P = 0.017; CHOP, P = 0.014). In the CHOP series, MVP was associated with high-risk group classification (P < 0.001), although this association was not seen in the smaller CMH cohort.

CONCLUSIONS

The association between MVP and poor outcome provides further support for the concept that angiogenesis plays an important role in determining the biological behavior of neuroblastoma tumors. Our results also indicate that angiogenesis is regulated differently in Schwannian stroma-rich versus stroma-poor neuroblastoma tumors. Further studies investigating the activity of angiogenic inhibitors in children with clinically aggressive stroma-poor neuroblastoma are warranted.

摘要

目的

肿瘤血管系统紊乱,肾小球样微血管增殖(MVP)在某些成人癌症中已被确定为预后不良的指标。为了确定MVP(包括神经母细胞瘤中的肾小球样MVP)的临床意义,我们首先检查了51名在儿童纪念医院(CMH)确诊的儿童肿瘤切片中的血管结构,随后在费城儿童医院(CHOP)构建的组织微阵列上评估了154例神经母细胞瘤肿瘤。

实验设计

检查苏木精-伊红(H&E)切片中结构异常血管的存在情况,并通过对CD31和血管性血友病因子进行免疫染色以突出内皮细胞,对α-平滑肌肌动蛋白进行免疫染色以突出周细胞,进一步进行特征描述。壁增厚且包含完整一层肥大内皮细胞以及额外几层血管壁细胞的肿瘤被分类为MVP阳性。评估MVP与既定临床病理特征及预后之间的关联。

结果

在两个系列中,MVP均与神经鞘基质少的组织学显著相关(CMH,P = 0.008;CHOP,P < 0.001),且生存概率降低(CMH,P = 0.017;CHOP,P = 0.014)。在CHOP系列中,MVP与高危组分类相关(P < 0.001),尽管在较小的CMH队列中未观察到这种关联。

结论

MVP与不良预后之间的关联进一步支持了血管生成在决定神经母细胞瘤肿瘤生物学行为中起重要作用这一概念。我们的结果还表明,富含神经鞘基质与基质少的神经母细胞瘤肿瘤中血管生成的调节方式不同。有必要进一步研究血管生成抑制剂在临床上侵袭性强的基质少的神经母细胞瘤儿童中的活性。

相似文献

1
Prominent microvascular proliferation in clinically aggressive neuroblastoma.在临床侵袭性神经母细胞瘤中显著的微血管增殖。
Clin Cancer Res. 2007 Jun 15;13(12):3499-506. doi: 10.1158/1078-0432.CCR-07-0237.
2
Clinicopathological considerations on angiogenic potential in neuroblastoma Schwannian stroma - poor tumours.神经母细胞瘤中低施万细胞基质肿瘤血管生成潜力的临床病理考量
Folia Neuropathol. 2007;45(1):1-8.
3
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.SPARC是一种关键的雪旺氏细胞衍生抑制剂,可控制神经母细胞瘤肿瘤血管生成。
Cancer Res. 2002 Dec 15;62(24):7357-63.
4
Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors.癌症相关成纤维细胞的存在与神经母细胞瘤肿瘤中的雪旺氏基质呈负相关。
Mod Pathol. 2009 Jul;22(7):950-8. doi: 10.1038/modpathol.2009.52. Epub 2009 May 1.
5
'Cross-talk' between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis.雪旺氏基质与成神经细胞之间的“串扰”促进成神经细胞瘤的肿瘤分化并抑制血管生成。
Cancer Lett. 2005 Oct 18;228(1-2):125-31. doi: 10.1016/j.canlet.2005.01.056.
6
Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior.大细胞神经母细胞瘤:一种具有侵袭性临床行为的神经母细胞瘤独特表型。
Cancer. 2004 Jan 15;100(2):390-7. doi: 10.1002/cncr.20005.
7
Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. A light microscopic and immunohistochemical study of formalin-fixed, routinely processed material.人类胶质和转移性脑肿瘤中微血管增殖的细胞成分。对福尔马林固定、常规处理材料的光学显微镜和免疫组织化学研究。
Acta Neuropathol. 1993;85(5):508-14. doi: 10.1007/BF00230490.
8
A correlation of microvascular density and proliferative activity to clinical and histological characteristics in neuroblastoma.神经母细胞瘤中微血管密度和增殖活性与临床及组织学特征的相关性。
Neoplasma. 2006;53(3):247-52.
9
Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.非小细胞肺癌中肿瘤细胞与基质细胞血管生成标志物表达的反向预后影响
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6649-57. doi: 10.1158/1078-0432.CCR-07-0414.
10
Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.血管生成细胞因子在儿童霍奇金淋巴瘤中的免疫组化表达
Pathol Res Pract. 2008;204(2):89-96. doi: 10.1016/j.prp.2007.11.005. Epub 2008 Jan 18.

引用本文的文献

1
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.神经母细胞瘤诊断、治疗与研究的新趋势
Mol Neurobiol. 2025 May;62(5):6423-6466. doi: 10.1007/s12035-024-04680-w. Epub 2025 Jan 13.
2
Sexually dimorphic computational histopathological signatures prognostic of overall survival in high-grade gliomas via deep learning.通过深度学习构建的性二态计算组织病理学特征对高级别胶质瘤患者总生存期的预测。
Sci Adv. 2024 Aug 23;10(34):eadi0302. doi: 10.1126/sciadv.adi0302.
3
Narrative review: precision medicine applications in neuroblastoma-current status and future prospects.
叙述性综述:精准医学在神经母细胞瘤中的应用——现状与未来展望
Transl Pediatr. 2024 Jan 29;13(1):164-177. doi: 10.21037/tp-23-557. Epub 2024 Jan 24.
4
Dynamic Changes in Microvascular Density Can Predict Viable and Non-Viable Areas in High-Risk Neuroblastoma.微血管密度的动态变化可预测高危神经母细胞瘤中的存活和非存活区域。
Cancers (Basel). 2023 Feb 1;15(3):917. doi: 10.3390/cancers15030917.
5
Applications and prospects of targeted therapy for neuroblastoma.神经母细胞瘤靶向治疗的应用与前景
World J Pediatr Surg. 2020 Jul 2;3(2):e000164. doi: 10.1136/wjps-2020-000164. eCollection 2020.
6
Alternative Vascularization Mechanisms in Tumor Resistance to Therapy.肿瘤对治疗产生抗性的替代性血管生成机制。
Cancers (Basel). 2021 Apr 15;13(8):1912. doi: 10.3390/cancers13081912.
7
Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.联合重组人血管内皮抑制素与细胞毒药物治疗复发性弥漫性胶质母细胞瘤:一项回顾性研究。
BMC Cancer. 2020 Jan 8;20(1):24. doi: 10.1186/s12885-019-6467-6.
8
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.MRI 成像对神经母细胞瘤血流血管的研究预测了其对抗血管生成治疗的反应。
Cancer Res. 2019 Jun 1;79(11):2978-2991. doi: 10.1158/0008-5472.CAN-18-3412. Epub 2019 Mar 15.
9
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.贝伐单抗、伊立替康和替莫唑胺联合治疗难治性或复发性神经母细胞瘤:一项II期研究结果
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26448. Epub 2017 Jan 23.
10
Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.细胞外基质组成在高危患者队列中定义了一个神经母细胞瘤的超高危组。
Br J Cancer. 2016 Aug 9;115(4):480-9. doi: 10.1038/bjc.2016.210. Epub 2016 Jul 14.